Document Detail

PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study.
MedLine Citation:
PMID:  7901927     Owner:  NLM     Status:  MEDLINE    
AIMS AND BACKGROUND: The aim of the present study was to determine, retrospectively, whether the immunohistochemical expression of two biologic markers of aggressively, P-glycoprotein (P-gp) and PCNA/cyclin (PCNA), could be related to response to chemotherapy and prognosis in locally advanced breast cancer. METHODS: PC 10 Mab was used to determine the proliferation index (PCNA) and C-219 Mab to determine P-gp in 25 locally advanced breast carcinomas subjected to preoperative chemotherapy with MDR-related drugs. RESULTS: P-gp and PCNA were expressed in 76% and 100% of the tumors, respectively. No case of high P-gp expression was associated with good chemosensitivity, and all P-gp-negative cases showed the best chemotherapeutic response. P-gp and PCNA were both highly expressed in patients who developed local-regional or distant metastases. No recurrence was associated with a negative or low P-gp score. CONCLUSIONS: Statistical analysis showed that high P-gp expression was related to a poor response to chemotherapy and a short disease-free survival. A high PCNA score was not found to be significant for predicting chemosensitivity or survival.
G Botti; G Chiappetta; G D'Aiuto; E de Angelis; A De Matteis; M Montella; A Picone; F Cascione
Related Documents :
20061047 - The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of t...
9778627 - Overexpression of transforming growth factor-beta1 in scirrhous carcinoma of the stomac...
15532797 - Nuclear survivin expression predicts poor outcome in cholangiocarcinoma.
8895667 - Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicat...
25318587 - Pleomorphic xanthoastrocytoma: natural history and long-term follow-up.
15900007 - Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for interme...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Tumori     Volume:  79     ISSN:  0300-8916     ISO Abbreviation:  Tumori     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-12-14     Completed Date:  1993-12-14     Revised Date:  2008-12-12    
Medline Journal Info:
Nlm Unique ID:  0111356     Medline TA:  Tumori     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  214-8     Citation Subset:  IM    
Istituto Nazionale dei Tumori, Fondazione G. Pascale, Napoli, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, Neoplasm / analysis*
Biological Markers / analysis
Breast Neoplasms / chemistry*,  drug therapy,  mortality,  pathology
Carrier Proteins / analysis*
Membrane Glycoproteins / analysis*
Middle Aged
Neoplasm Proteins / analysis*
Nuclear Proteins / analysis*
Proliferating Cell Nuclear Antigen
Retrospective Studies
Survival Analysis
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Biological Markers; 0/Carrier Proteins; 0/Membrane Glycoproteins; 0/Neoplasm Proteins; 0/Nuclear Proteins; 0/P-Glycoprotein; 0/Proliferating Cell Nuclear Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The transglutaminase hypothesis for the action of tetanus toxin.
Next Document:  Frequency of the IVS-10nt546 mutation in 44 Turkish phenylketonuria patients.